IP Library › Granted Patent US 12,465,635
Granted Patent B2
US 12,465,635 · App. 17/545,894 · Granted Nov 11, 2025

Methods of treating inflammatory arthritis using secukinumab

Inventors: Shephard Mpofu (Oberwil, CH); Hanno Richards (Therwil, CH); Karthinathan Thangavelu (Geneva, CH); Matthias Machacek (Allschwil, CH)
Assignee: NOVARTIS AG
A61K39/3955A61K31/519A61K45/06C07K16/244A61K2039/505A61K2039/545A61K2039/55C07K2317/21C07K2317/34C07K2317/76C07K2317/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,635
App. No.
17/545,894
Granted
Nov 11, 2025
Kind
B2
Abstract

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).

Claims (18)

1 . A method of treating inflammatory arthritis in a patient in need thereof using secukinumab, wherein the method comprises subcutaneously administering every 2 weeks or every 4 weeks about 75 mg to about 300 mg of secukinumab to the patient, wherein the inflammatory arthritis is spondyloarthropathy or polymyalgia rheumatica.

2 . The method according to claim 1 , wherein the inflammatory arthritis is spondyloarthropathy.

3 . The method according to claim 2 , wherein the spondyloarthropathy is ankylosing spondylitis or psoriatic arthritis.

4 . The method according to claim 2 , wherein the spondyloarthropathy is psoriatic arthritis.

5 . The method according to claim 4 , comprising subcutaneously administering a dose of 75 mg, 150 mg, or 300 mg secukinumab.

6 . The method according to claim 2 , comprising subcutaneously administering a dose of 75 mg, 150 mg, or 300 mg secukinumab.

7 . The method according to claim 1 , wherein the inflammatory arthritis is polymyalgia rheumatica.

8 . The method according to claim 1 , wherein secukinumab is subcutaneously administered at a dose of about 75 mg to about 300 mg every 2 weeks to the patient.

9 . The method according to claim 1 , wherein secukinumab is subcutaneously administered at a dose of about 75 mg to about 300 mg every 4 weeks to the patient.

10 . The method according to claim 9 , wherein secukinumab is subcutaneously administered at a dose of about 75 mg every 4 weeks to the patient.

11 . The method of claim 9 , wherein secukinumab is administered at a dose of about 150 mg every 4 weeks to the patient.

12 . The method of claim 11 , wherein the patient was previously administered about 150 mg secukinumab by subcutaneous injection weekly for 4 weeks.

13 . The method of claim 9 , wherein secukinumab is administered at a dose of about 300 mg every 4 weeks to the patient.

14 . The method of claim 13 , wherein the patient was previously administered about 300 mg secukinumab by subcutaneous injection weekly for 4 weeks.

15 . The method of claim 1 , wherein the patient was previously administered about 75 mg secukinumab by subcutaneous injection weekly for 4 weeks.

16 . The method according to claim 1 , wherein the patient is an adult.

17 . A method of treating inflammatory arthritis in a patient in need thereof using secukinumab, wherein the method comprises: a) administering three to five weekly doses of about 75 mg to about 300 mg secukinumab subcutaneously to the patient, and then b) subsequently administering a maintenance dose of about 75 mg to about 300 mg secukinumab subcutaneously every two weeks to every four weeks to the patient during a maintenance regimen.

18 . The method according to claim 17 , wherein the maintenance regimen comprises a subcutaneous administration every 4 weeks.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: RICHARDS, HANNO
To: NOVARTIS AG
Reel/Frame 058999/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: THANGAVELU, KARTHINATHAN
To: NOVARTIS AG
Reel/Frame 058999/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: MACHACEK, MATTHIAS
To: NOVARTIS PHARMA AG
Reel/Frame 059000/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 059000/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: MPOFU, SHEPHARD
To: NOVARTIS AG
Reel/Frame 059100/0781 →
Continuity (5)
Division 16439423 · Jun 12, 2019
Division 15654854 · Jul 20, 2017
Division 13877585
Provisional Application 61410533 · Nov 5, 2010
Related Publication 20220193234A1 · Jun 23, 2022
References Cited (332)
US 5250442A · Orestes · 1993 [cited by applicant]
US 6309636B1 · do Couto · 2001 [cited by applicant]
US 8119131B2 · DiPadova · 2012 [cited by applicant]
US 9717791B2 · Guettner et al. · 2017 [cited by applicant]
US 9744234B2 · Mpofu et al. · 2017 [cited by applicant]
US 11280479B2 · Meyer et al. · 2022 [cited by applicant]
US 20050147609A1 · Filvaroff · 2005 [cited by applicant]
US 20080044423A1 · Cochrane · 2008 [cited by applicant]
US 20100080812A1 · Auer et al. · 2010 [cited by applicant]
US 20100266608A1 · Cooreman et al. · 2010 [cited by applicant]
US 20120045848A1 · Haugland et al. · 2012 [cited by applicant]
US 20130202610A1 · Guettner et al. · 2013 [cited by applicant]
US 20130209480A1 · Mpofu et al. · 2013 [cited by applicant]
US 20180008706A1 · Mpofu et al. · 2018 [cited by applicant]
CN 104244979A · 2014 [cited by applicant]
EP 3111954A1 · 2017 [cited by applicant]
JP 2000186048 · 2000 [cited by applicant]
JP 2015519311A · 2015 [cited by applicant]
WO 2006013107 · 2006 [cited by applicant]
WO 2006013107A1 · 2006 [cited by applicant]
WO 2006096491A2 · 2006 [cited by applicant]
WO 2007059188A1 · 2007 [cited by applicant]
WO 2007117749A2 · 2007 [cited by applicant]
WO 2007149032A1 · 2007 [cited by applicant]
WO 2008030611A2 · 2008 [cited by applicant]
WO 2008054603A2 · 2008 [cited by applicant]
WO 2008121615A2 · 2008 [cited by applicant]
WO 2008156865A2 · 2008 [cited by applicant]
WO 2009002859A1 · 2008 [cited by applicant]
WO 2009149168A2 · 2009 [cited by applicant]
WO 2010006060A2 · 2010 [cited by applicant]
WO 2010056804A1 · 2010 [cited by applicant]
WO 2010065491A2 · 2010 [cited by applicant]
WO 2010102251A2 · 2010 [cited by applicant]
WO 2012059598A2 · 2012 [cited by applicant]
WO 2012082573A1 · 2012 [cited by applicant]
WO 2013077907A1 · 2013 [cited by applicant]
WO 2013158821A2 · 2013 [cited by applicant]
WO 2014155278A2 · 2014 [cited by applicant]
WO 2017068472A1 · 2017 [cited by applicant]
Eric J Yang et al: “Secukinumab in the treatment of psoriasis: patient selection and perspectives”, Psoriasis: Targets and Therapy, vol. 8, Oct. 1, 2018 (Oct. 1, 2018), pp. 75-82, XP55723379, DOI: 10.2147/PTT.S146004. [cited by applicant]
P J Mease: “Psoriatic arthritis assessment tools in clinical trials”, Annals of the Rheumatic Diseases, vol. 64, No. suppl_2, Mar. 1, 2005 (Mar. 1, 2005), pp. ii49-ii54, XP55723382, GB ISSN: 0003-4967, DOI: 10.1136/ard.… [cited by applicant]
Anonymous: “Rheumatologists chose ACR50, ACR70 over ACR20 as endpoints when prescribing psoriatic arthritis drugs”, Heallo Psoriatic Disease, Apr. 30, 2014 (Mar. 30, 2014), XP55723384, Retrieved from the Internet: URL:h… [cited by applicant]
Letko et al., Invest Opthalmol Vis Sci, 2013, 54:E-Abstract 5929. [cited by applicant]
Porter et al., J Pharm Sci, 2000, 89:297-310. [cited by applicant]
Wang et al., Clin. Pharma. Ther., 2008, 84:548-558. [cited by applicant]
Haller et al., Pharma Tech, 2007, 10(31). [cited by applicant]
Zhao et al., Acta Pharmacologica Sinica, 2012, 33:1339-1347. [cited by applicant]
Kagan et al., Pharm. Res., 2012, 29:490-499. [cited by applicant]
Ogura et al., Immunity, 2008, 29:628-636. [cited by applicant]
Mok et al., Clin Rheumatol, 2013, 32:1429-1435. [cited by applicant]
Wolbink et al., Curr. Opin. Rheum., 2009, 21(3):211-215. [cited by applicant]
Salvana and Salata, Clin. Microbio. Reviews, 2009, 22(2):274-290. [cited by applicant]
NCT01109940, updated Jun. 22, 2010. [cited by applicant]
Wang et al., J Clin Pharmacol, 2009, 49:1012-1024. [cited by applicant]
Lalonde et al., Clin. Pharma. & Ther., 2007, 82:21-32. [cited by applicant]
Sacks et al., JAMA, 2014, 311:378-384. [cited by applicant]
Cross et al., Pharmacoepidemiology & Drug Safety, 2002, 11:439-446. [cited by applicant]
Mould and Green, Biodrugs, 2010, 24(1):23-29. [cited by applicant]
Genovese et al., Ann. Rheum. Dis., 2013, 72:863-869. [cited by applicant]
Remicade Package Insert, dated Aug. 1998. [cited by applicant]
Remicade Package Insert, dated Oct. 2015. [cited by applicant]
Keizer et al., Clin Pharmacokinet, 2010, 49(8):493-507. [cited by applicant]
Meibohm, 2006, The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs:, Chapter 1, p. 6 in Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Devel… [cited by applicant]
Kiltz et al., Curr Opin Rheumatol, 2012, 24(3):252-260. [cited by applicant]
Goodman, “Secukinumab Successful in Spondylitis, Psoriatic Arthritis”, Medscape Medical News, 2014, p. 1 (available at www.medscape.com). [cited by applicant]
Freeman, “Secukinumab improves Patient-Reported Outcomes in Ankylosing Spondylitis”, Rheumatology News, 2016, (Available at www.mdedge.com/rheumatologynews). [cited by applicant]
Kelly, “Secukinumab Effective for Ankylosing Spondylitis in Phase 3 Trials”, Medscape Medical News (2015). [cited by applicant]
Press Release (2015) “Novartis announces one-year results demonstrating sustained efficacy with investigational secukinumab in ankylosing spondylitis patients at EULAR”, MarketWatch (available at www.marketwatch.com). [cited by applicant]
Chen and Liu, “Sulfasalazine for ankylosing spondylitis”, Cochrane Database Syst Rev, 2005, 2:CD004800. [cited by applicant]
Declaration of Brian Porter (including exhibits) dated Feb. 21, 2017. [cited by applicant]
Declaration of Renard Didier (including exhibits) dated Mar. 2, 2017. [cited by applicant]
Clinical Trials database entry NCT01109940, dated Jun. 22, 2010. [cited by applicant]
Yang et al., “Crystalline monoclonal antibodies for subcutaneous delivery”, PNAS, 2003, 100(12):6934-6939. [cited by applicant]
Dicke et al., “Secukinumab in the Treatment of Noninfectious UveitisL result of Three Randomized Controlled Clinical Trials”, Ophthalmology, 2013, 120(4):777-787. [cited by applicant]
Buggage et al., “the Study of IL-17A Expression as a Biomarker for Patients with Active Noninfectious Uveitis Treated With AIN457”, Assoc for Research in Vision and Ophthalmology, abstract 3799D1066, Session 383, Presen… [cited by applicant]
Recker et al., “Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis”, Bone, 2004, 34(5):890-899. [cited by applicant]
Zhao et al., “Clinical pharmacology considerations in biologics development”, Acta Pharm Sinica, 2012, 33:1339-1347. [cited by applicant]
Sacks et al., “Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012”, JAMA, 2014, 311:378-384. [cited by applicant]
Richter et al., “Mechanistic Determinates of Biotherapeutics Absorption Following SC Adinistration”, AAPS Journal, 2012, 14:559-570. [cited by applicant]
Porter et al., “Lymphatic transport of proteins after s.c. injections: implications of animal model selection”, Adv. Drug Delivery Reviews, 2001, 50:157-171. [cited by applicant]
Wang et al., “Monolonal Antibody Pharmacokinetics and Pharmacodynamics”, Clin Pharmacol Ther., 2008, 84 (5):548-558. [cited by applicant]
Declaration of Dr. Oliver Sander dated Oct. 19, 2015. [cited by applicant]
Clinical Trial database entry NCT00928512 (dated Jun. 29, 2015). [cited by applicant]
Clinical Trial database entry NCT 00809159 (dated Jun. 22, 2010). [cited by applicant]
Declaration of Dr. Diane Mould, dated Jan. 29, 2017, filed in U.S. Appl. No. 10/163,657. [cited by applicant]
Balague et al., “Understanding autoimmune disease: new targets for drug discovery”, Drug Discovery Today, 2009, 14 (19/20):926-934. [cited by applicant]
John Collett Ed-Aulton Me (ED) 2: “Dosage Regimens”, 2001, Pharmaceutics: the Science of Dosage Form Design, London, Churchill Livingstone, GB, pp. 275-288, XP003030862, ISBN: 978-0-443-05517-1. [cited by applicant]
Romao et al., “Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?”, BMC Medicine, 2013, 11(17):1-24. [downloaded at http://www.bio… [cited by applicant]
Machold et al., “Very Recent onset rheumatoid arthritis: clinical and seological patient characteristics associated with radiographic progression over the first years of disease”, Rheumatology, 2007, 46:342-349. [cited by applicant]
Potter et al., “Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheum… [cited by applicant]
Yildirim et al., “Associations between Acute Phase Reactant Levels and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis”, Annals of Clinical & Laboratory Science, 2004, 34(4):423-426. [cited by applicant]
Scott et al., “Seminar—Rheumatoid Arthritis”, Lancet, 2010, 376:1094-1108. [cited by applicant]
Gladman et al., “Psoriatic arthritis: epidemiology, clinical features, course and outcome”, Ann Rheum Dis, 2005, 64 (Suppl 11):ii14-ii17. [cited by applicant]
Boehncke and Menter“, Burden of Disease: Psoriasis and Psoriatic Arthritis”, Am J Clin Dermatol, 2013, 14:377-388. [cited by applicant]
Psoriatic Arthritis (PsA):A Distinct, Complex disease downloaded http://discoverpsa.com on Feb. 2, 2016. [cited by applicant]
Nash et al., “Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus adalimumab up to 48 weeks using a matching-adjusted indirect comparison”, Ann Rheum Dis, 2016, 75(Suppl 2):353… [cited by applicant]
Strand et al., “Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison”, Arthritis Rheumatol., 2016, 68 (Suppl 10). [cited by applicant]
Xenofen et al., “Interleukin-17A Blockade with Secukinuman Reduced Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaing”, Arthritis and Rheumatism, 75t… [cited by applicant]
Baeten et al., “L7-The anti-IL-17A monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis”, Late Breaking Abstracts: American College of Rheumatology 2… [cited by applicant]
Lubberts, “Th17 cytokines and arthritis”, Seminars IN Immunopathology, Springer, Berlin, DE, 2010, 32(1):43-53 XP019800827, ISSN: 1863-2300. [cited by applicant]
McInnes, “Anti-Interleukin' 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of PSoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial”, Arthritis and Rheumatism, … [cited by applicant]
Novartis: “View of NCT00809614 on 2010_04_29”, ClinicalTrials.gov archive, Apr. 29, 2010, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT00809614/2010_04_29 [Retrieved Sep. 14, 2016}. [cited by applicant]
Novartis “View of NCT00809159 on 2010_06_22”, CLinicalTrials.gov archive, Jun. 22, 2010, REtrieved from the internet, https://clinicaltrials.gov/archive/NCT00809159/2010_06_22 [Retrieved Sep. 7, 2016]. [cited by applicant]
Genovese et al., “Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomized, placebo controlled study”, Ann Rheum Dis, 2013, 72:863-869. [cited by applicant]
Sieper et al., “Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active anylosing spondylitis: results from the MEASURE 2 Study”, Ann Rheum, 2016, doi.10.1136/annrheumdis-2016-210023 (e-pub … [cited by applicant]
McInnes et al., “Secukinumab, a human anti-interleikin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial”, Lancet, 2015, 386(9999):19… [cited by applicant]
Kavanaugh, “Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratifies by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study”, J. Rh… [cited by applicant]
Hueber et al., “Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo controlled trial”, Gut, 2012, 61:1693-1700. [cited by applicant]
Gottlieb et al., “Guidelines of care for the management of psoriases and psoriatic arthritis”, J Am Acad Dermatol, 2008, 58:851-864. [cited by applicant]
Van der Horst-Bruinsma et al., “A systematic coparison of rheumatoid arthritis and anylosing spondylitis”, Clin. Exp. Rheumatol., 2009, 27(4Supple 55):S43-9. [cited by applicant]
Vandooren et al., “Absence of a Classically Activated Macrophage Cytokine Signature in Peripheral Sponylarthritis Including Psoriatic Arthritis”, Arthritis Rheum, 2009, 60(4):966-975. [cited by applicant]
Meibohm, “The role of pharmacokinetics and pharmacodynamics in the development of biotech drugs”, Wiley-VCH Verlag Gmbh & Co. KGaA, 2006, Chapter 1. [cited by applicant]
Keizer et al., “Clinical Pharmacokinetics of therapeutic monoclonal antibodies”, CLin Pharmacokinet, 2010, 49 (8):493-507. [cited by applicant]
Wang et al., “Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials”, J Clin Pharmacol., 2009, 49:1012-1024. [cited by applicant]
Baeten et al., Lancet, 2013, 382(9906):1705-13. [cited by applicant]
Dougados and Baeten, Lancet, 2011, 377:2127-2137. [cited by applicant]
Vandporen et al., Arthritis Rheum, 2009, 80:966-975. [cited by applicant]
Melis et al., Ann. Rheum. Dis., 2010, 69:618-623. [cited by applicant]
Ciccia et al., Arthritis Rheum, 2009, 60:955-965. [cited by applicant]
Sieper et al, Ann Rheum Dis, 2014, 73:95-100. [cited by applicant]
Sieper et al., Abstract 536, presented ACR/ARHP Annual Meeting, Boston, Massachusetts, US, 2014. [cited by applicant]
Deodhar, Ann. Rheum, Dis, 2015, 74:1144. [cited by applicant]
Maksymnowych, Ann. Rheum. Dis., 2016, 75(Suppl 2):98. [cited by applicant]
Van der Heijde, Arthr. Rheum., 2006, 54(7):2136-2146. [cited by applicant]
Clinicaltrials.gov database entry NCT01870284, last updated Sep. 15, 2014. [cited by applicant]
Clinicaltrials.gov databse entry NCT02696785, first received Feb. 26, 2016. [cited by applicant]
Press Release, Amgen and Wyeth, dated Jul. 24, 2003. [cited by applicant]
Braun et al., Expert Op. Biological Therapy, 2016, 16(5):711-722. [cited by applicant]
Sieper et al, Ann Rheum Dis, 2016, 0:1-5 doi:1031136/annrheumdis-2016-210023. [cited by applicant]
Marzo-Ortega et al., Ann Rheum Dis, 2016, 75Suppl 2:812-813. [cited by applicant]
Sieper et al., Ann Rheum Dis, 2015, 74(6):1051-1057. [cited by applicant]
Song et al., Ann Rheum Dis, 2011, 70:1108-1110. [cited by applicant]
Haibel et al., Ann Rheum Dis, 2005, 64:296-298. [cited by applicant]
Song et al., Arthritis Rheum, 2010, 62:1290-1297. [cited by applicant]
Braun et al., Expert Opin Emerg Drugs, 2015, 20(1):1-14. [cited by applicant]
Maldonado-Ficco et al., Clin Rheumatol, 2016, 35:2151-2161. [cited by applicant]
Van der Heijde et al., Arthritis Rheum, 2005, 52:582-591. [cited by applicant]
Davis et al., Arthritis Rheum, 2003, 48:3230-3236. [cited by applicant]
Inman et al., Arthritis Rhem, 2008, 58:3402-3412. [cited by applicant]
Landewe et al., Ann Rheum Dis, 2014, 73:39-47. [cited by applicant]
Sieper et al., Ann Rheum Dis, 2011, 10.1136/annrheumdis-2011-200358. [cited by applicant]
Clinical Trial NCT01107457 (Apr. 20, 2010). [cited by applicant]
Saber et al., “Remission in psoriatic arthritis: is it possible and how can it be predicted?”, Arthritis Research & Therapy, 12(3):R94. (2010). [cited by applicant]
Wang, “Instability, stabilization, and formulation of liquid protein pharmaceuticals”, International Journal of Pharmaceutics, 185:129-188. (1999). [cited by applicant]
Falconer, “Advances in liquid formulations of parenteral therapeutic proteins”, Biotechnology Advances, 37(7):107412. (2019). [cited by applicant]
Griffiths et al., “Psoriasis and Psoriatic Arthritis: Immunological Aspects and Therapeutic Guidelines,” Clin Exp Rheumatol, Jan.-Feb. 2006, vol. 24, Suppl. 40, pp. S72-S78. [cited by applicant]
ACR Call for Late-Breaking Abstracts, Guidelines for Submission, Nov. 10-14, 2022. [cited by applicant]
Hennigan, et al., Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy, Core Evidence, 2008, 295-305, 2(4). [cited by applicant]
Jandus, et al., Increased Numbers of Circulating Polyfunctional Th17 Memory Cells in Patients With Seronegative Spondylarthritedes, Arthritis and Rheumatism, Aug. 2008, 2307-2317, 58(8). [cited by applicant]
Newsome, et al., The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?, British Journal of Clinical Pharmacology, May 22, 2008, 6-19, 66(1). [cited by applicant]
Zuidema et al., “Release and Absorption Rates of Intramuscularly and Subcutaneously Injected Pharmaceuticals,” International Journal of Pharmaceuticals, 1994, vol. 105, pp. 189-207. [cited by applicant]
Falconer, “Advances in Liquid Formulations of Parenteral Therapeutic Proteins,” Biotechnology Advances, 2019, vol. 37, pp. 1-9. [cited by applicant]
Haller, “Converting Intravenous Dosing to Subcutaneous Dosing,” Parenteral Formulation, 2007, pp. 118-132. [cited by applicant]
Igawa et al., “Reduced Elimination of IgG Antibodies by Engineering the Variable Region,” Protein Engineering Design & Selection, 2010, vol. 23, No. 5, pp. 385-392. [cited by applicant]
Boswell et al., “Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics,” Bioconjugate Chem., 2010, vol. 21, pp. 2153-2163. [cited by applicant]
Baraliakos, et al., Biologic Therapies for Spondyloartritis: What is new?, Current Rheumatology Reports, Aug. 2, 2012, 422-427, 14. [cited by applicant]
Baraliakos, et al., Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study, Annals of Rheumatic Diseases, Aug. 6, 2015, 4… [cited by applicant]
Baron-Faust, The IL-17 Superfamily: What Future for PsA?, Rheumatology Network, Mar. 18, 2014. [cited by applicant]
Chandran, et al., Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort, Journal of Rheumatology, 2008, 469-471, 35(3). [cited by applicant]
Clinical Trial NCT04209205, Dec. 24, 2019, available at https://www.clinicaltrials.gov/ct2/show/NCT04209205. [cited by applicant]
Cosentyx prescribing information, revised Jan. 2020. [cited by applicant]
Cosentyx Summary of Products Characteristics, Sep. 1, 2017. [cited by applicant]
Daikh, et al., Advances in managing ankylosing spondylitis, F1000 Prime Reports, Sep. 4, 2014, 6(78). [cited by applicant]
Danve, et al., IL-17 Inhibition in Axial Spondyloarthritis, Current Treatment Options in Rheumatology, Apr. 2, 2015, 221-230, 1. [cited by applicant]
Deodhar, et al., Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: Result from a phase 3 double-blind, randomized, placebo-controlled study, ACR/ARP Annual Meeting… [cited by applicant]
Deodhar, et al., Secukinumab 150 mg significantly improved signs and symptoms of non-radiographic axial spondyloarthritis: Result from a phase 3 double-blind, randomized, placebo-controlled study, ACR/ARP annual meeting… [cited by applicant]
Deodhar, et al., The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis, Annals of Rheumatic Diseases, 2016, 791-794, 75. [cited by applicant]
Fagerli, et al., Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study, Annals of Rheumatic Diseases, Apr. 5, 2013, 1840-1844, 72. [cited by applicant]
Gaffen, et al., The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing, Nature Reviews Immunology, Sep. 2014, 585-600, 14. [cited by applicant]
Genco, FDA Approval Of The First nr-AxSpA Biologics: Projecting Regulatory & Market Dynamics, Biosimilar Development, Feb. 27, 2019. [cited by applicant]
Goh, et al., Update on biologic therapies in ankylosing spondylitis: a literature review, International Journal of Rheumatic Disease, 2012, 445-454, 15. [cited by applicant]
Gottlieb, et al., Secukinumab Reduces Hscrp Levels in Subjects with Moderate-To-Severe Plaque Psoriasis and Concomitant Psoriatic Arthritis: A Sub-Analysis from the Phase 3 Erasure Study, Annals of the Rheumatic Disease… [cited by applicant]
Gottlieb, et al., Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multi… [cited by applicant]
Goulabchand, et al., Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials, Annals of Rheumatic Diseases, 201… [cited by applicant]
History of Changes for Study NCT00928512, Mar. 12, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT00928512. [cited by applicant]
History of Changes for Study NCT00995709, Oct. 14, 2009, available at https://www.clinicaltrials.gov/ct2/show/NCT00995709. [cited by applicant]
History of Changes for Study NCT01032915, Oct. 24, 2010, available at https://www.clinicaltrials.gov/study/NCT01032915. [cited by applicant]
History of Changes for Study NCT01071252, Feb. 18, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01071252. [cited by applicant]
History of Changes for Study NCT01090310, Sep. 28, 2010, available at https://www.clinicaltrials.gov/ct2/show/NCT01090310. [cited by applicant]
History of Changes for Study NCT01093846, Oct. 13, 2010, available at https://www.clinicaltrials.gov/study/NCT01093846. [cited by applicant]
History of Changes for Study NCT01095250, Oct. 13, 2010, available at https://clinicaltrials.gov/ct2/history/NCT01095250?A=6&B=6&C=merged. [cited by applicant]
History of Changes for Study NCT01103024, Oct. 15, 2010, available at https://clinicaltrials.gov/study/NCT01103024?a=2&tab=history. [cited by applicant]
History of Changes for Study NCT01327664, Mar. 31, 2011, available at https://clinicaltrials.gov/study/NCT01327664?tab=history&a=1. [cited by applicant]
History of Changes for Study NCT01350804, Sep. 23, 2011, available at https://clinicaltrials.gov/study/NCT01350804?tab=history&a=3. [cited by applicant]
History of Changes for Study NCT01358578, Aug. 17, 2011, available at https://clinicaltrials.gov/study/NCT01358578?tab=history&a=6. [cited by applicant]
History of Changes for Study NCT01365455, Oct. 12, 2011, available at https://clinicaltrials.gov/study/NCT01365455?a=10&tab=history. [cited by applicant]
History of Changes for Study NCT01377012, Sep. 28, 2011, available at https://clinicaltrials.gov/study/NCT01377012?a=4&tab=history. [cited by applicant]
History of Changes for Study NCT01392326, Sep. 23, 2011, available at https://clinicaltrials.gov/study/NCT01392326?tab=history&a=2. [cited by applicant]
History of Changes for Study NCT01406938, Aug. 15, 2011, available at https://clinicaltrials.gov/study/NCT01406938?a=2&tab=history. [cited by applicant]
History of Changes for Study NCT01412944, Aug. 8, 2011, available at https://clinicaltrials.gov/study/NCT01412944?tab=history&a=1. [cited by applicant]
Humira prescribing information, revised Mar. 2020. [cited by applicant]
Kavanaugh, et al., The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year, Annals of Rheumatic Diseases, Jan. 26, 2006, 1038-1043, 65. [cited by applicant]
Kavanaugh, et al., Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis, Annals of Rheumatic Diseases, Feb. 19, 2014, 1000-1006, 73. [cited by applicant]
Kocijan, et al., Anti-TNFs in axial spondyloarthritis, Wiener Medizinische Wochenschrift, Jan. 9, 2015, 10-13, 165. [cited by applicant]
Kunder, Treatment of the patients with psoriatic arthritis, Medical News, 2013, 34-41, 6. [cited by applicant]
Langley, et al., Secukinumab in Plaque Psoriasis—Results of Two Phase 3 Trials, N Engl J Med., Jul. 24, 2014, 326-338, 371(4). [cited by applicant]
Machado, et al., New developments in the diagnosis and treatment of axial spondyloartritis, Clinical Investigation, 2013, 153-171, 3(2). [cited by applicant]
Madej, et al., Cytokine Profiles in Axial Spondyloarthritis, Reumatologia, 2015, 9-13, 53(1). [cited by applicant]
Mantravadi, et al., Tumor necrosis factor inhibitors in psoriatic arthritis, Expert Review of Clinical Pharmacology, May 22, 2017, 899-910, 10(8). [cited by applicant]
Mcinnes, et al., Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs And Symptoms Of Psoriatic Arthritis In A 24-Week Multicenter; Double⋅-blind, Randomized, Placebo-Controlled Trial, Arthritis and Rheuma… [cited by applicant]
Mckee, Novartis' Cosentyx shown to inhibit joint damage in PsA, Pharma Times, Nov. 7, 2017. [cited by applicant]
Mease, et al., Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis, N Engl J Med., Jun. 12, 2014, 2295-2306, 370(24). [cited by applicant]
Mease, et al., Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis, Drugs, Feb. 25, 2014, 423-441, 74. [cited by applicant]
Mease, et al., Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study, ACR/ARHP Annual Meeting, Oct. 19, 2017. [cited by applicant]
Mease, Non anti-TNF biologics on SpA and PsA, Annals of Rheumatic Diseases, Jun. 8, 2012, abstract SP0147. [cited by applicant]
Mrowietz, et al., Definition of treatment goals for moderate to severe psoriasis: a European consensus, Archives for Dermatological Research, Jan. 2011, 1-10, 303. [cited by applicant]
Novartis announces result of Prevent Study, dated Nov. 12, 2019, downloaded Dec. 11, 2019. [cited by applicant]
Patel, et al., Effect of IL-17A blockade with secukinumab in autoimmune diseases, Annals of Rheumatic Diseases, 2013, 116-123, 72. [cited by applicant]
Poddubnyy, Axial spondyloarthritis: is there a treatment of choice, Therapeutic Advances in Musculoskeletal Disease, 2013, 45-54, 5(1). [cited by applicant]
Poddubnyy, et al., Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis—a five-year update, Expert Opinion on Biological Therapy, 2013, 1599-1611, 13(11). [cited by applicant]
Poddubnyy, et al., Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis, Best Practice & Research Clinical Rheumatology, 2014, 807-818, 28. [cited by applicant]
Rodriguez, et al., Old and new treatment targets in axial spondyloarthritis, RMD Open, Apr. 5, 2015, 1. [cited by applicant]
Rudwaleit, et al., The development of Assessment of Spondyloarthritis international Society classification criterai for axial spondyloarthritis (part I): classification of paper patients by expert opinion including unce… [cited by applicant]
Shostak, et al., Back pain of inflammatory genesis: seronegative spondyloarthropathy—the main approaches to diagnosis and therapy, The Clinician, Jan. 2011, 5. [cited by applicant]
Sieper, et al., Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1), Clinical and epidemiological research, Jul. 7, 2… [cited by applicant]
Song, et al., Consistently Good Clinical Response in Patients with early Axial Spondyloartritis after 3 Years of continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial, The Journal of Rheumatology, 2014… [cited by applicant]
Stelara Highlights of Prescribing Information, revised Sep. 2016. [cited by applicant]
Urano, Diagnosis of spondyloarthritis: from ankylosing spondylitis to axial spondyloarthritis, Inflammation and Immunity, 2013, 79-85, 21(1). [cited by applicant]
Van Der Heijde, et al., Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised pl… [cited by applicant]
Van Der Heijde, et al., Psoriatic arthritis imaging: a review of scoring methods, Annals of Rheumatic Diseases, 2005, 61-64, 64(suppl. 2). [cited by applicant]
Ward, et al., American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axi… [cited by applicant]
Weitz, et al., Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis, Expert Opinion on Biological Therapy, 2014, 515-526, 14(4). [cited by applicant]
Weselman, Psoriatic Arthritis, American College of Rheumatology, 2017. [cited by applicant]
Novartis, Clinical Trial Results, Protocol No. CAIN457F2304, study completion date Nov. 2020. [cited by applicant]
Smolen et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs”, Ann. Rheum. Dis., 2010, 1-12, downloaded from ard.bmj.com on Oct. 27… [cited by applicant]
Aletaha et al., “2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative”, Ann Rheum. Dis., 2010, 69:1580-1588. [downloaded from… [cited by applicant]
Genovese et al., “Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment” Results of a Phase IIb Study, Art… [cited by applicant]
Hueber et al., “Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis”, Science Translational Medicine, American Association for the Advancement of Science, 2010, … [cited by applicant]
Genovese et al., “LY2439821, a humanized anti-leukin-17 monoclonal antobody, in the treatment of patients and rheumatoid arthritis: A Phase I randomized, d-blind, placebo-controlled, proof-of-concept study”, Arthritis &… [cited by applicant]
Yoshida et al., “Methotrexate suppresses inflammatory agonist induced interleukin 6 synthesis in osteoblasts”, Journal of Rheumatology, 2005, 32(5):787-795. [cited by applicant]
Hou et al., “Methotrexate amellorates pristane-induced arthritis by decreasing IFN-[gamma] and IL-17A expressions”, Journal of Zhejiang University—Science B, 2011, 12(1):40-46. [cited by applicant]
Clinical trial NCT00809159 (Dec. 16, 2008). [cited by applicant]
Clinical trial NCT00928512 (Jun. 25, 2009). [cited by applicant]
NCT01169844 on Jul. 23, 2010, clinicaltrials.gov archive, [online] Jul. 23, 2010. Internet <URL:https://clinicaltrials.gov/archive/NCTO_1169844/2010_07_23>. [cited by applicant]
Baeten et al., “Secukinumab, a Monocional ANtibody to Interleukin-17A, SignificantlyImproves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Int… [cited by applicant]
Mease and McInnes, “Secukinumab: A New Treatment Option for Psoriatic Arthritis”, Rheumatol Ther, 2016, 3:5-29. [cited by applicant]
Sieper et al., “Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active anylosing spondylitis: results from the MEASURE 2 Study”, Ann Rheum Dis, 2017, 76:571-575. [cited by applicant]
Cosentyx Product Monograph, Canada, pp. 1-44, Aug. 17, 2017. [cited by applicant]
Olivieri et al., “Emerging drugs for psoriatic arthritis”, Expert Opinion on Emerging Drugs, 2010, 15(3):399-414. [cited by applicant]
ACR/ARHP Call for abstracts Guidelines_Oct. 2010. [cited by applicant]
Anonymous: ““Object”—Definition & Meaning—Merriam-Webster”, , Dec. 8, 2021 (Dec. 8, 2021), pp. 1-15, XP055870736, Retrieved from the Internet: URL:https://www.merriam-webster.com/dictionary/object [retrieved on Dec. 8, … [cited by applicant]
Chioato, et al., Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects Exposed to Secukinumab 150 Mg: Preliminary Study Results., Arthritis and Rheumatism, Oct. 2011, S711, 63(10). [cited by applicant]
Cosentyx prescribing information, revised Jan. 2016. [cited by applicant]
History of changes for Study NCT00669916, submitted on Apr. 9, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00669916?V_5=View. [cited by applicant]
History of changes for Study NCT00669942, submitted on Mar. 27, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00669942?A=5&B=5&C=merged. [cited by applicant]
History of changes for Study NCT00805480, submitted on Jan. 28, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00805480?V_4=View. [cited by applicant]
History of changes for Study NCT00809614, submitted on Oct. 14, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00809614?A=5&B=5&C=merged. [cited by applicant]
History of changes for Study NCT00995709, submitted on Aug. 13, 2015, available at https://clinicaltrials.gov/ct2/history/NCT00995709?V_7=View. [cited by applicant]
History of changes for Study NCT01032915, submitted on Oct. 8, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01032915?V_4=View. [cited by applicant]
History of changes for Study NCT01071252, submitted on Feb. 12, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01071252?V_1=View. [cited by applicant]
History of changes for Study NCT01090310, submitted on Dec. 8, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01090310?V_2=View. [cited by applicant]
History of changes for Study NCT01093846 submitted on Jan. 22, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01093846?V_2=View. [cited by applicant]
History of changes for Study NCT01095250, submitted on Oct. 5, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01095250?A=6&B=6&C=merged. [cited by applicant]
History of changes for Study NCT01103024, submitted on May 2, 2012, available at https://clinicaltrials.gov/ct2/history/NCT01103024?A=2&B=2&C=merged. [cited by applicant]
History of changes for Study NCT01109940, submitted on Nov. 15, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01109940?V_2=View. [cited by applicant]
History of changes for Study NCT01169844, submitted on Nov. 16, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01169844?A=1&B=1&C=merged. [cited by applicant]
History of changes for Study NCT01327664, submitted on Dec. 5, 2013, available at https://clinicaltrials.gov/ct2/history/NCT01327664?V_1=View. [cited by applicant]
History of changes for Study NCT01350804, submitted on May 4, 2016, available at https://clinicaltrials.gov/ct2/history/NCT1350804?A=3&B=3&C=merged. [cited by applicant]
History of changes for Study NCT01358578, submitted on Mar. 29, 2019, available at https://clinicaltrials.gov/ct2/history/NCT01358578?A=6&B=6&C=merged. [cited by applicant]
History of changes for Study NCT01365455, submitted on Mar. 20, 2019, available at https://clinicaltrials.gov/ct2/history/NCT01365455?A=10&B=10&C=merged. [cited by applicant]
History of changes for Study NCT01377012, submitted on Feb. 9, 2017, available at https://clinicaltrials.gov/ct2/history/NCT1377012?A=4&B=4&C=merged. [cited by applicant]
History of changes for Study NCT01392326, submitted on Jan. 5, 2016, available at https://clinicaltrials.gov/ct2/history/NCT01392326?A=2&B=2&C=merged. [cited by applicant]
History of changes for Study NCT01406938, submitted on Apr. 30, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01406938?A=2&B=2&C=merged. [cited by applicant]
History of changes for Study NCT01412944, submitted on Mar. 17, 2015, available at https://clinicaltrials.gov/ct2/history/NCT01412944?A=1&B=1&C=merged. [cited by applicant]
Kivitz, et al., Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study, Rheumatology and Therapy, Aug. 18, 2018, 447-462, 5. [cited by applicant]
Mayo Clinic_Apr. 30, 2020_Diagnosis and treatment of Uveitis https://www.mayoclinic.org/diseasesconditions/uveitis/diagnosis-treatment/drc-20378739?p=1. [cited by applicant]
Nash, et al., Secukinumab for psoriatic arthritis: comparative effectiveness results versus etanercept up to 24 weeks using a matching-adjusted indirect comparison, International Journal of Rheumatic Diseases, 2016, 163… [cited by applicant]
NHSC Publication, May 2010, AIN-457 for posterior uveitis, 5 pages. [cited by applicant]
Online publication_Sep. 27, 2011_Arthritis & Rheumatism. [cited by applicant]
Online publication_Dec. 9, 2011_Arthritis & Rheumatism. [cited by applicant]
Pavelka, et al., Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, doubleblind phase 3 study, MEASURE 3, Arthritis Research and Therapy, Dec. 22, 2017, 27 pa… [cited by applicant]
Proprietor's letter to the Examining Division_Feb. 15, 2018. [cited by applicant]
Reichert, Antibody-based therapeutics to watch in 2011, mAbs, Jan. 1, 2011, 76-99, 3(1). [cited by applicant]
Samson, et al., An Open-Label Proof-Of Concept Study to Assess the Efficacy of AIN457 in Patients With Noninfectious Uveitis, Invest Ophthalmol Vis Sci., Apr. 2010, 51. [cited by applicant]
Tak, et al., A1N457 Shows a Good Safety Profile and Clinical Benefit in Patients with Active Rheumatoid Arthritis (RA) Despite Methotrexate Therapy: 16-Weeks Results From a Randomized Proof-of-Concept Trial, ACR/ARHP Sc… [cited by applicant]
Taltz prescribing information, revised Aug. 2019, 1 page. [cited by applicant]
U.S. Appl. No. 61/410,533, filed Nov. 5, 2010. [cited by applicant]
Wayback Machine_Oct. 29, 2010_www.rheumatology.org, retrieved from the Internet: URL - https://web.archive.org/web/20101029090319/http:/www.rheumatology.org/. [cited by applicant]
Wiley: “Publication Date of D2”, Dec. 9, 2021 (Dec. 9, 2021), pp. 1-2, XP55871165, [retrieved on Dec. 8, 2021]. [cited by applicant]
Benhamou et al_2010_Rheumatology. [cited by applicant]
Baeten et al_2010_Arthritis and Rheumatism. [cited by applicant]
ClinicalTrials.gov Archive, Jun. 22, 2010, p. 1-2, https://clinicaltrials.gov/archive/NTC01109940/2010_06_22. [cited by applicant]
Science Translational Medicine, Oct. 1, 2010, 2(52):Article 52RA72, pp. 1-9. [cited by applicant]
Expert Opinion Emerging Drugs, 15(3):399-414, Sep. 2010, CR12. [cited by applicant]
ClinicalTrials.gov; 16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis, pp. 1-9. [cited by applicant]
Late-Breaking Abstracts: American College of Rheumatology, 2010 Annual Scientific Meeting. [cited by applicant]
Baeten et al., “The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis”, Arthritis & Rhematism, 2010, vol. 62:3840-3841. [cited by applicant]
Arthritis & Rheumatism, Journal of the American College of Rheumatology, vol. 63, No. 10, Abstract Supplemental. [cited by applicant]
Baeten et al., “Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis”, The New England Journal of Medicine, 2015, 2534-2548. [cited by applicant]
Methods of Treating Rheumatoid Arthritis Using IL-17 Antagonists, pp. 1-99, FF Text. [cited by applicant]
ClinicalTrials.gov Archive, History of Changes for Study: NCT00809159, Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis, U.S. National Library of Medicine,… [cited by applicant]
ClinicalTrials.gov Archive, History of Changes for Study, NCT00928512, Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX), pp. 1-9. [cited by applicant]
Hueber et al., “Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis”, 2010, 2(52)52ra72:1-11. [cited by applicant]
Van der Heijde et al., “Adalimumab Effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial, Extended Report”, Ann Rheum Dis., 2009, pp. 922-929. [cited by applicant]
Davis et al., “Recombinant Human Tumor Necrosis Factor Receptor (etanercept) for Treating Ankylosing Spondylitis, A Randomized, Controlled Trial”, Arthritis & Rheumatism, 2003, 48(11):3230-3236. [cited by applicant]
Inman et al., “Efficacy and Safety of Golimumab in Patients with Ankylosing Spondylitis, Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial”, Arthritis & Rheumatism, 2005, 52(2):582-591. [cited by applicant]
ClinicalTrials.gov Archive, NCT00809614 Apr. 29, 2010. [cited by applicant]
ClinicalTrials.gov Archive, NCT01169844, Jul. 23, 2010. [cited by applicant]
Science Translational Medicine, Oct. 1, 2010 vol. 2, N52/Article No. 52RA72, pp. 1-9. [cited by applicant]
Press Release of Novarts dated Oct. 24, 2011, D10-Press release of Novartis.pdf, Other-evidence-4.pdf. [cited by applicant]
ClinicalTrials.gov, NCT01359943, printout of https://clinicaltrials.gov/ct2/history/NCT01359943?V2=View#StudyPageTop, Oct. 18, 2011. [cited by applicant]
ClinicalTrials.gov, NCT01649375, (MEASURE 2), printout of https://clinicaltrials.gov/ct2/show/NCT01649375(post-published). [cited by applicant]
Baeten et al., “The Anti-IL17A Monoclonal Antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis”, Annals of the Rheumatic Diseases, vol. 70, No. 3, Abstract #OP0… [cited by applicant]
Cimzia (Ref TM) (certolizumab pegol) FDA label dated Jul. 2010. [cited by applicant]
Genovese et al., “Secukinumab (AIN457), a novel monoclonal antibody targeting IL-17A demonstrates efficacy in active rheumatoid arthritis patients despite stable methotrexate treatment results of a phase IIb study”, Art… [cited by applicant]
Genovese et al., “Secukinumab (AIN457) showed a rapid decrease activity in patients with active rheumatoid arthritis patients including those with high inflammatory burden”, Annals of the Rheumatic Diseases, vol. 70, No… [cited by applicant]
Ness, (Sep. 12, 2011) “Surveying the pipeline of biologics to treat inflammatory conditions”, Pharmacy Times, Aug. 2011; printout of https://www.pharmacytimes.com/publications/issue/2011/august2011/surveying-the-pipelin… [cited by applicant]
ClinicalTrials.gov, NCT01358175 (MEASURE1), printout of https://clinicaltrials.gov/ct2/history/NCT01358175?V2=View#StudyPageTop, Oct. 20, 2011. [cited by applicant]
Press Release of Novartis dated Oct. 24, 2011, print out of https://www.foxnews.com/health/study-drug-helps-with-psoriasis-symptoms. [cited by applicant]
Inman et al., “Efficacy and Safety of Gollmumab in Patients With Ankylosing SPondylitis”, Arthritis & Rheumatism, 2008, 58(11):34020-3412. [cited by applicant]
Van der Heijde et al., “Efficacy and Safety of Infliximab in Patients with Ankylosing Spondylitis”, Arthritis & Rheumatism, 2005, 52(2):582-591. [cited by applicant]
Van der Heijde et al., “Efficacy and Safety of Adalimumab in Patients with Ankylosing Spondylitis”, Arthritis & Rheumatism, 2006, 54(7):2136-2146. [cited by applicant]
Song et al., “Different Response to Rituximab in Tumor Necrosis Factor Blocker-Naive Patients with Active Ankylosing Spondylitis and in Patients in Whom Tumor Necrosis Factor Blockers Have Failed”, Arthritis & Rheumatis… [cited by applicant]
Halibel et al., “Open label trial of anakinra in active ankylosing spondylitis over 24 weeks”, Ann Rheum Dios, 2005, 64:296-298. [cited by applicant]
Song et al., “Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study”, Ann Rheum Dis, 2011, 70:1108-1110. [cited by applicant]
Sieper et al., “Assessnebt if short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials”, Ann Rheum Dis, 2014, 73:95-100. [cited by applicant]
Sieper et al., “Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)”, Ann Rheum Dis, 2015, 74:1051-1057. [cited by applicant]
Dougados and Baeten, “Spondyloarthritis”, Lancet, 2011, 377:2127-2137. [cited by applicant]
Braun et al., “2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis”, Ann Rheum Dis, 2011, 70:896-904. [cited by applicant]
Landews et al., “Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind, randomised, placebo-controlled Phase 3 study”, Ann Rh… [cited by applicant]
Kagen et al., “Subcultaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats”, Pharm Res, 2012, 18:490-499. [cited by applicant]
Zhao et al., “The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment P… [cited by applicant]
Tang et al., “Pharmacokinetic Aspects of Biotechnology Products”, Journal of Pharmaceutical Sciences, 2004, 93 (9):2184-2204. [cited by applicant]
Richter et al., “Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration”. The AAPS Journal, 2012, 14(3). [cited by applicant]
TAMIFLU(TM)(oseltamivir phosphate) Capsules and for Oal Suspension Package insert, Rev, Jan. 2008. [cited by applicant]
MALARONE Package insert, Revised, Jun. 2013. [cited by applicant]
Maksymowych et al., “Secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus adalimumab using a matching-adjusted indirect comparison”, Absrtact OP114 presented at the 25th Euro… [cited by applicant]
Nash et al., Secukinumab for psoriatic arthritis: comparative effectiveness results versus etanercept up to 24 weeks using a matching-adjusted indirect comparison, International Journal of Rheumatic Diseases, 2016, 19(S… [cited by applicant]
Declaration of Diane Mould, dated Jan. 29, 2014, filed in U.S. Appl. No. 10/163,657, filed Feb. 7, 2014. [cited by applicant]
Menter et al., “Guidelines of care for the management of psoriasis and psoriatic arthritis”, J Am Acad Dermatol 2011, pp. 137-174. [cited by applicant]
Gossec et al., “European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies”, Ann Rheum Dis, 2012, 71:4-12. [cited by applicant]